04/14/2026

Recent Oncology Related FDA Approvals and Expanded Indications

FDA Approves Bristol Myers Squibb's Opdivo® (nivolumab) with Chemotherapy for Previously Untreated Hodgkin Lymphoma

FDA Approves Corcept Therapeutics' Lifyorli (relacorilant) with Nab-paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

More Info